| amlodipine vs chlorthalidone | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 1.06 [0.98 1.14] | p=1.00 | 0 | 8851 | 1 | ALLHAT (amlodipine vs chlor, diabetic subgroup), | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 1.02 [0.93 1.12] | p=1.00 | 0 | 8851 | 1 | ALLHAT (amlodipine vs chlor, diabetic subgroup), | | stroke (fatal and non fatal) | 0.89 [0.74 1.07] | p=1.00 | 0 | 8851 | 1 | ALLHAT (amlodipine vs chlor, diabetic subgroup), | | microvascular events | no data | | Non fatal MI | no data | | All cause death | 0.96 [0.87 1.06] | p=1.00 | 0 | 8851 | 1 | ALLHAT (amlodipine vs chlor, diabetic subgroup), | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| amlodipine vs fosinopril | No demonstrated result suggested cardiovascular events by 51% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.49 [0.26 0.93] | p=0.04 | 0 | 380 | 1 | FACET, | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 1.29 [0.55 3.01] | p=1.00 | 0 | 380 | 1 | FACET, | | stroke (fatal and non fatal) | 2.47 [0.76 8.03] | p=1.00 | 0 | 380 | 1 | FACET, | | microvascular events | no data | | Non fatal MI | no data | | All cause death | 0.81 [0.22 2.99] | p=1.00 | 0 | 380 | 1 | FACET, | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| amlodipine vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.88 [0.69 1.12] | p=1.00 | 0 | 1136 | 1 | IDNT (amlodipine vs PBO), | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | microvascular events | 1.04 [0.86 1.25] | p=1.00 | 0 | 1136 | 1 | IDNT (amlodipine vs PBO), | | Non fatal MI | no data | | All cause death | 0.88 [0.66 1.18] | p=1.00 | 0 | 1136 | 1 | IDNT (amlodipine vs PBO), | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| amlodipine vs atenolol | No demonstrated result suggested cardiovascular events by 15% (not demonstrated) suggested Cardiovascular death by 23% (not demonstrated) suggested stroke (fatal and non fatal) by 23% (not demonstrated) suggested All cause death by 10% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.85 [0.77 0.94] | p=0.04 | 0 | 19257 | 1 | ASCOT-BPLA, | | Cardiovascular death | 0.77 [0.65 0.90] | p=0.04 | 0 | 19257 | 1 | ASCOT-BPLA, | | stroke (fatal and non fatal) | 0.77 [0.67 0.90] | p=0.04 | 0 | 19257 | 1 | ASCOT-BPLA, | | Coronary event | 0.90 [0.79 1.03] | p=1.00 | 0 | 19257 | 1 | ASCOT-BPLA, | | Fatal MI | no data | | Non fatal MI | no data | | Heart failure | 0.84 [0.67 1.06] | p=1.00 | 0 | 19257 | 1 | ASCOT-BPLA, | | Diabetes onset | no data | | Angina | no data | | Peripheral arterial disease | no data | | End stage renal disease | no data | | Revascularization | no data | | All cause death | 0.90 [0.81 1.00] | p=0.04 | 0 | 19257 | 1 | ASCOT-BPLA, | | Fatal stroke | no data | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| amlodipine vs chlorthalidone | No demonstrated result suggested Heart failure by 37% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 1.04 [0.98 1.10] | p=1.00 | 0 | 24303 | 1 | ALLHAT (CCB vs diu), | | Cardiovascular death | 1.01 [0.91 1.12] | p=1.00 | 0 | 24303 | 1 | ALLHAT (CCB vs diu), | | stroke (fatal and non fatal) | 0.94 [0.83 1.07] | p=1.00 | 0 | 24303 | 1 | ALLHAT (CCB vs diu), | | Coronary event | 0.99 [0.90 1.08] | p=1.00 | 0 | 24303 | 1 | ALLHAT (CCB vs diu), | | Fatal MI | 0.95 [0.79 1.15] | p=1.00 | 0 | 24303 | 1 | ALLHAT (CCB vs diu), | | Non fatal MI | no data | | Heart failure | 1.37 [1.23 1.52] | p=0.04 | 0 | 24303 | 1 | ALLHAT (CCB vs diu), | | Diabetes onset | no data | | Angina | 0.99 [0.89 1.09] | p=1.00 | 0 | 24303 | 1 | ALLHAT (CCB vs diu), | | Peripheral arterial disease | 0.88 [0.75 1.02] | p=1.00 | 0 | 24303 | 1 | ALLHAT (CCB vs diu), | | End stage renal disease | 1.13 [0.90 1.41] | p=1.00 | 0 | 24303 | 1 | ALLHAT (CCB vs diu), | | Revascularization | 1.10 [1.00 1.21] | p=1.00 | 0 | 24303 | 1 | ALLHAT (CCB vs diu), | | All cause death | 0.96 [0.89 1.04] | p=1.00 | 0 | 24303 | 1 | ALLHAT (CCB vs diu), | | Fatal stroke | 0.94 [0.73 1.22] | p=1.00 | 0 | 24303 | 1 | ALLHAT (CCB vs diu), | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| amlodipine vs lisinopril | No demonstrated result suggested stroke (fatal and non fatal) by 17% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.97 [0.91 1.03] | p=1.00 | 0 | 18102 | 1 | ALLHAT (CCB vs ACEI), | | Cardiovascular death | 0.97 [0.87 1.09] | p=1.00 | 0 | 18102 | 1 | ALLHAT (CCB vs ACEI), | | stroke (fatal and non fatal) | 0.83 [0.72 0.95] | p=0.04 | 0 | 18102 | 1 | ALLHAT (CCB vs ACEI), | | Coronary event | 1.00 [0.91 1.11] | p=1.00 | 0 | 18102 | 1 | ALLHAT (CCB vs ACEI), | | Fatal MI | 1.07 [0.86 1.33] | p=1.00 | 0 | 18102 | 1 | ALLHAT (CCB vs ACEI), | | Non fatal MI | no data | | Heart failure | no data | | Diabetes onset | no data | | Angina | 0.93 [0.85 1.02] | p=1.00 | 0 | 18102 | 1 | ALLHAT (CCB vs ACEI), | | Peripheral arterial disease | 0.85 [0.72 1.01] | p=1.00 | 0 | 18102 | 1 | ALLHAT (CCB vs ACEI), | | End stage renal disease | 1.02 [0.80 1.31] | p=1.00 | 0 | 18102 | 1 | ALLHAT (CCB vs ACEI), | | Revascularization | 1.01 [0.91 1.13] | p=1.00 | 0 | 18102 | 1 | ALLHAT (CCB vs ACEI), | | All cause death | 0.96 [0.88 1.04] | p=1.00 | 0 | 18102 | 1 | ALLHAT (CCB vs ACEI), | | Fatal stroke | 0.79 [0.60 1.03] | p=1.00 | 0 | 18102 | 1 | ALLHAT (CCB vs ACEI), | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| amlodipine vs metoprolol | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | stroke (fatal and non fatal) | no data | | Coronary event | no data | | Fatal MI | no data | | Non fatal MI | no data | | Heart failure | no data | | Diabetes onset | no data | | Angina | no data | | Peripheral arterial disease | no data | | End stage renal disease | no data | | Revascularization | no data | | All cause death | 0.70 [0.36 1.33] | p=1.00 | 0 | 658 | 1 | AASK (amlodipine vs metoprolol), | | Fatal stroke | no data | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| amlodipine vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | stroke (fatal and non fatal) | no data | | Coronary event | no data | | Fatal MI | no data | | Non fatal MI | no data | | Heart failure | no data | | Diabetes onset | no data | | Angina | no data | | Peripheral arterial disease | no data | | End stage renal disease | no data | | Revascularization | no data | | All cause death | 0.90 [0.65 1.24] | p=1.00 | 0 | 1136 | 1 | IDNT (amlodipine vs pbo), | | Fatal stroke | no data | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| amlodipine plus benazepril vs hydrochlorothiazide plus benazepril | No demonstrated result suggested cardiovascular events by 18% (not demonstrated) suggested Coronary event by 21% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.82 [0.72 0.92] | p=0.04 | 0 | 11506 | 1 | ACCOMPLISH, | | Cardiovascular death | 0.80 [0.62 1.04] | p=1.00 | 0 | 11506 | 1 | ACCOMPLISH, | | stroke (fatal and non fatal) | 0.84 [0.66 1.09] | p=1.00 | 0 | 11506 | 1 | ACCOMPLISH, | | Coronary event | 0.79 [0.62 1.00] | p=0.04 | 0 | 11506 | 1 | ACCOMPLISH, | | Fatal MI | no data | | Non fatal MI | no data | | Heart failure | no data | | Diabetes onset | no data | | Angina | no data | | Peripheral arterial disease | no data | | End stage renal disease | no data | | Revascularization | 0.87 [0.75 1.01] | p=1.00 | 0 | 11506 | 1 | ACCOMPLISH, | | All cause death | 0.90 [0.75 1.08] | p=1.00 | 0 | 11506 | 1 | ACCOMPLISH, | | Fatal stroke | no data | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Diabetic patients : 4 trials - FACET - IDNT (amlodipine vs PBO) - ALLHAT (CCB vs ACEI) - ALLHAT (amlodipine vs chlor, diabetic subgroup)
| amlodipine vs chlorthalidone | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 1.06 [0.98 1.14] | p=1.00 | 0 | 8851 | 1 | ALLHAT (amlodipine vs chlor, diabetic subgroup), | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 1.02 [0.93 1.12] | p=1.00 | 0 | 8851 | 1 | ALLHAT (amlodipine vs chlor, diabetic subgroup), | | stroke (fatal and non fatal) | 0.89 [0.74 1.07] | p=1.00 | 0 | 8851 | 1 | ALLHAT (amlodipine vs chlor, diabetic subgroup), | | microvascular events | no data | | Non fatal MI | no data | | All cause death | 0.96 [0.87 1.06] | p=1.00 | 0 | 8851 | 1 | ALLHAT (amlodipine vs chlor, diabetic subgroup), | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| amlodipine vs fosinopril | No demonstrated result suggested cardiovascular events by 51% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.49 [0.26 0.93] | p=0.04 | 0 | 380 | 1 | FACET, | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 1.29 [0.55 3.01] | p=1.00 | 0 | 380 | 1 | FACET, | | stroke (fatal and non fatal) | 2.47 [0.76 8.03] | p=1.00 | 0 | 380 | 1 | FACET, | | microvascular events | no data | | Non fatal MI | no data | | All cause death | 0.81 [0.22 2.99] | p=1.00 | 0 | 380 | 1 | FACET, | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| amlodipine vs lisinopril | No demonstrated result suggested stroke (fatal and non fatal) by 17% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.97 [0.91 1.03] | p=1.00 | 0 | 18102 | 1 | ALLHAT (CCB vs ACEI), | | Cardiovascular death | 0.97 [0.87 1.09] | p=1.00 | 0 | 18102 | 1 | ALLHAT (CCB vs ACEI), | | stroke (fatal and non fatal) | 0.83 [0.72 0.95] | p=0.04 | 0 | 18102 | 1 | ALLHAT (CCB vs ACEI), | | Coronary event | 1.00 [0.91 1.11] | p=1.00 | 0 | 18102 | 1 | ALLHAT (CCB vs ACEI), | | Fatal MI | 1.07 [0.86 1.33] | p=1.00 | 0 | 18102 | 1 | ALLHAT (CCB vs ACEI), | | Non fatal MI | no data | | Heart failure | no data | | Diabetes onset | no data | | Angina | 0.93 [0.85 1.02] | p=1.00 | 0 | 18102 | 1 | ALLHAT (CCB vs ACEI), | | Peripheral arterial disease | 0.85 [0.72 1.01] | p=1.00 | 0 | 18102 | 1 | ALLHAT (CCB vs ACEI), | | End stage renal disease | 1.02 [0.80 1.31] | p=1.00 | 0 | 18102 | 1 | ALLHAT (CCB vs ACEI), | | Revascularization | 1.01 [0.91 1.13] | p=1.00 | 0 | 18102 | 1 | ALLHAT (CCB vs ACEI), | | All cause death | 0.96 [0.88 1.04] | p=1.00 | 0 | 18102 | 1 | ALLHAT (CCB vs ACEI), | | Fatal stroke | 0.79 [0.60 1.03] | p=1.00 | 0 | 18102 | 1 | ALLHAT (CCB vs ACEI), | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| amlodipine vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.88 [0.69 1.12] | p=1.00 | 0 | 1136 | 1 | IDNT (amlodipine vs PBO), | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | microvascular events | 1.04 [0.86 1.25] | p=1.00 | 0 | 1136 | 1 | IDNT (amlodipine vs PBO), | | Non fatal MI | no data | | All cause death | 0.88 [0.66 1.18] | p=1.00 | 0 | 1136 | 1 | IDNT (amlodipine vs PBO), | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Nephropathy: 2 trials - IDNT (amlodipine vs pbo) - AASK (amlodipine vs metoprolol)
| amlodipine vs metoprolol | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | stroke (fatal and non fatal) | no data | | Coronary event | no data | | Fatal MI | no data | | Non fatal MI | no data | | Heart failure | no data | | Diabetes onset | no data | | Angina | no data | | Peripheral arterial disease | no data | | End stage renal disease | no data | | Revascularization | no data | | All cause death | 0.70 [0.36 1.33] | p=1.00 | 0 | 658 | 1 | AASK (amlodipine vs metoprolol), | | Fatal stroke | no data | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| amlodipine vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | stroke (fatal and non fatal) | no data | | Coronary event | no data | | Fatal MI | no data | | Non fatal MI | no data | | Heart failure | no data | | Diabetes onset | no data | | Angina | no data | | Peripheral arterial disease | no data | | End stage renal disease | no data | | Revascularization | no data | | All cause death | 0.90 [0.65 1.24] | p=1.00 | 0 | 1136 | 1 | IDNT (amlodipine vs pbo), | | Fatal stroke | no data | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients undergoing dialysis : 1 trials - Tepel et al
| amlodipine vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.62 [0.33 1.16] | p=1.00 | 0 | 251 | 1 | Tepel et al, | | Cardiovascular death | no data | | All cause death | 0.78 [0.38 1.60] | p=1.00 | 0 | 251 | 1 | Tepel et al, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients with additional risk factor: 4 trials - ASCOT-BPLA - ALLHAT (CCB vs diu) - ACCOMPLISH - ALLHAT (CCB vs ACEI)
| amlodipine vs atenolol | No demonstrated result suggested cardiovascular events by 15% (not demonstrated) suggested Cardiovascular death by 23% (not demonstrated) suggested stroke (fatal and non fatal) by 23% (not demonstrated) suggested All cause death by 10% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.85 [0.77 0.94] | p=0.04 | 0 | 19257 | 1 | ASCOT-BPLA, | | Cardiovascular death | 0.77 [0.65 0.90] | p=0.04 | 0 | 19257 | 1 | ASCOT-BPLA, | | stroke (fatal and non fatal) | 0.77 [0.67 0.90] | p=0.04 | 0 | 19257 | 1 | ASCOT-BPLA, | | Coronary event | 0.90 [0.79 1.03] | p=1.00 | 0 | 19257 | 1 | ASCOT-BPLA, | | Fatal MI | no data | | Non fatal MI | no data | | Heart failure | 0.84 [0.67 1.06] | p=1.00 | 0 | 19257 | 1 | ASCOT-BPLA, | | Diabetes onset | no data | | Angina | no data | | Peripheral arterial disease | no data | | End stage renal disease | no data | | Revascularization | no data | | All cause death | 0.90 [0.81 1.00] | p=0.04 | 0 | 19257 | 1 | ASCOT-BPLA, | | Fatal stroke | no data | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| amlodipine vs chlorthalidone | No demonstrated result suggested Heart failure by 37% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 1.04 [0.98 1.10] | p=1.00 | 0 | 24303 | 1 | ALLHAT (CCB vs diu), | | Cardiovascular death | 1.01 [0.91 1.12] | p=1.00 | 0 | 24303 | 1 | ALLHAT (CCB vs diu), | | stroke (fatal and non fatal) | 0.94 [0.83 1.07] | p=1.00 | 0 | 24303 | 1 | ALLHAT (CCB vs diu), | | Coronary event | 0.99 [0.90 1.08] | p=1.00 | 0 | 24303 | 1 | ALLHAT (CCB vs diu), | | Fatal MI | 0.95 [0.79 1.15] | p=1.00 | 0 | 24303 | 1 | ALLHAT (CCB vs diu), | | Non fatal MI | no data | | Heart failure | 1.37 [1.23 1.52] | p=0.04 | 0 | 24303 | 1 | ALLHAT (CCB vs diu), | | Diabetes onset | no data | | Angina | 0.99 [0.89 1.09] | p=1.00 | 0 | 24303 | 1 | ALLHAT (CCB vs diu), | | Peripheral arterial disease | 0.88 [0.75 1.02] | p=1.00 | 0 | 24303 | 1 | ALLHAT (CCB vs diu), | | End stage renal disease | 1.13 [0.90 1.41] | p=1.00 | 0 | 24303 | 1 | ALLHAT (CCB vs diu), | | Revascularization | 1.10 [1.00 1.21] | p=1.00 | 0 | 24303 | 1 | ALLHAT (CCB vs diu), | | All cause death | 0.96 [0.89 1.04] | p=1.00 | 0 | 24303 | 1 | ALLHAT (CCB vs diu), | | Fatal stroke | 0.94 [0.73 1.22] | p=1.00 | 0 | 24303 | 1 | ALLHAT (CCB vs diu), | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| amlodipine vs lisinopril | No demonstrated result suggested stroke (fatal and non fatal) by 17% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.97 [0.91 1.03] | p=1.00 | 0 | 18102 | 1 | ALLHAT (CCB vs ACEI), | | Cardiovascular death | 0.97 [0.87 1.09] | p=1.00 | 0 | 18102 | 1 | ALLHAT (CCB vs ACEI), | | stroke (fatal and non fatal) | 0.83 [0.72 0.95] | p=0.04 | 0 | 18102 | 1 | ALLHAT (CCB vs ACEI), | | Coronary event | 1.00 [0.91 1.11] | p=1.00 | 0 | 18102 | 1 | ALLHAT (CCB vs ACEI), | | Fatal MI | 1.07 [0.86 1.33] | p=1.00 | 0 | 18102 | 1 | ALLHAT (CCB vs ACEI), | | Non fatal MI | no data | | Heart failure | no data | | Diabetes onset | no data | | Angina | 0.93 [0.85 1.02] | p=1.00 | 0 | 18102 | 1 | ALLHAT (CCB vs ACEI), | | Peripheral arterial disease | 0.85 [0.72 1.01] | p=1.00 | 0 | 18102 | 1 | ALLHAT (CCB vs ACEI), | | End stage renal disease | 1.02 [0.80 1.31] | p=1.00 | 0 | 18102 | 1 | ALLHAT (CCB vs ACEI), | | Revascularization | 1.01 [0.91 1.13] | p=1.00 | 0 | 18102 | 1 | ALLHAT (CCB vs ACEI), | | All cause death | 0.96 [0.88 1.04] | p=1.00 | 0 | 18102 | 1 | ALLHAT (CCB vs ACEI), | | Fatal stroke | 0.79 [0.60 1.03] | p=1.00 | 0 | 18102 | 1 | ALLHAT (CCB vs ACEI), | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| amlodipine plus benazepril vs hydrochlorothiazide plus benazepril | No demonstrated result suggested cardiovascular events by 18% (not demonstrated) suggested Coronary event by 21% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.82 [0.72 0.92] | p=0.04 | 0 | 11506 | 1 | ACCOMPLISH, | | Cardiovascular death | 0.80 [0.62 1.04] | p=1.00 | 0 | 11506 | 1 | ACCOMPLISH, | | stroke (fatal and non fatal) | 0.84 [0.66 1.09] | p=1.00 | 0 | 11506 | 1 | ACCOMPLISH, | | Coronary event | 0.79 [0.62 1.00] | p=0.04 | 0 | 11506 | 1 | ACCOMPLISH, | | Fatal MI | no data | | Non fatal MI | no data | | Heart failure | no data | | Diabetes onset | no data | | Angina | no data | | Peripheral arterial disease | no data | | End stage renal disease | no data | | Revascularization | 0.87 [0.75 1.01] | p=1.00 | 0 | 11506 | 1 | ACCOMPLISH, | | All cause death | 0.90 [0.75 1.08] | p=1.00 | 0 | 11506 | 1 | ACCOMPLISH, | | Fatal stroke | no data | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
